Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: A high incidence of 11q13/CCND1 and 16q23/MAF

International Journal of Hematology

Volumn 87, Issue 3, 2008, Pages 260-265

  Takimoto, Madoka ^a   Ogawa, Kohei ^a   Kato, Yo ^a   Saito, Tasuku ^a   Suzuki, Takao ^a   Irei, Michiko ^a   Shibuya, Yasushi ^a   Suzuki, Yoshinori ^a   Kato, Masayuki ^a   Inoue, Yasuyuki ^a   Takahashi, Masatomo ^a   Sugimori, Hiroki ^b   Miura, Ikuo ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DAITO BUNKA UNIVERSITY   (Japan)

Author keywords

14q32 IGH translocation; Chromosome 13; FISH; Myeloma; Prognostic factor

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 13; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MALE; MONOSOMY; MULTIPLE MYELOMA; PROGNOSIS;

AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 13; COHORT STUDIES; FEMALE; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSLOCATION, GENETIC;

EID: 46149093968     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0039-x     Document Type: Article

References (36)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-87.
2. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-18.
3. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16:3832-42.
4. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-502.
5. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474-80.
6. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-20.
7. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109:3489-95.
8. Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-20.
9. Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-73.
10. 2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566-71.
11. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 1997;90:526-34.
12. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-9.
13. Nimura T, Miura I, Kobayashi Y, Yoshioka T, Kume M, Takahashi N, et al. Cytogenetic study of 48 patients with multiple myeloma and related disorders. J Clin Exp Hematop. 2003;43:53-60.
14. ISCN. An International System for Human Cytogenetic Nomenclature, Shaffer LG, Tommerup N editors. Basel: S. Karger; 2005. pp. 1-120.
15. Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer. 1997;18:84-93.
16. Harrison CJ, Mazzullo H, Cheung KL, Gerrard G, Jalali GR, Mehta A, et al. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results. Br J Haematol. 2003;120:944-52.
17. Gutiérrez NC, García JL, Hernández JM, Lumbreras E, Castellanos M, Rasillo A, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood. 2004;104:2661-6.
18. Dewald GW, Therneau T, Larson D, Lee YK, Smoley S, Paternoster S, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005;106:3553-8.
19. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674-81.
20. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91:4457-63.
21. Chesi M, Nardini E, Lim RSC, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3 and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid Transcripts. Blood. 1998;92:3025-34.
22. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and Cytogenetics of Multiple Myeloma. Cancer Res. 2004;64:1546-58.
23. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333-8.
24. Iida S, Ueda R. Multistep tumorigenesis of multiple myeloma: Its molecular delineation. Int J Hematol. 2003;77:207-12.
25. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735-41.
26. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia. 2003;17:2032-5.
27. Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260-4.
28. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579-83.
29. Nakazawa N, Nishida K, Tamura A, Kobayashi M, Iwai T, Horiike S, et al. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies. Cancer Genet Cytogenet. 2000;117:89-96.
30. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120:40-61.
31. Lymphoma Study Group of Japanese Pathologists. The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50:696-702.
32. Shaughnessy J Jr, Tian E, Sawyer J, Bumm K, Landes R, Badros A, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505-11.
33. Chiecchio L, Protheroe RKM, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610-7.
34. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15:981-6.
35. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-6.
36. H status and CD38 expression. Blood. 2006;108:3152-60.